CompletedNot Applicable

Translating ECHOS2 Into an mHealth Platform

United States73 participantsStarted 2023-07-05

Plain-language summary

Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low. This study aims to assess the feasibility of an mHealth motivational interviewing platform called Computerized Authoring Intervention Software (CIAS) in childhood cancer survivors. Participants will be recruited from the Childhood Cancer Survivorship Study.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older * Diagnosed with cancer at age 17 or younger * 2 or more years after completion of cancer therapy * Receipt of cardiotoxic therapy (Any dose of anthracycline or 15 Gy chest radiation involving cardiac structures) * No history of cardiomyopathy * Have not received an echocardiogram in the past 5 years

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in health belief model (HBM) construct scale of knowledge about echocardiograms and the effects of their treatment on health

Timeframe: From baseline survey to post-test survey (expected to be about 1 week)

Change in self-determination theory (SDT) construct scale of competence, defined by confidence in getting an echocardiogram

Timeframe: From baseline survey to post-test survey (expected to be about 1 week)

Change in self-determination theory (SDT) construct scale of autonomy, defined by the perceived choice of getting an echocardiogram

Timeframe: From baseline survey to post-test survey (expected to be about 1 week)

Change in self-determination theory (SDT) construct scale of relatedness, as defined by the effect of social norms/influence on the patient's decision of getting echocardiogram

Timeframe: From baseline survey to post-test survey (expected to be about 1 week)

Change in movement toward screening

Timeframe: From post-test survey to 1 month follow-up (expected to be about 1 month and 1 week)

Trial details

NCT IDNCT05923242

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Childhood Cancer trials